Europe: B-Cell Therapy Moves Into IgG4-Related Disease
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the therapeutic indication of Uplizna (inebilizumab, Amgen Europe) to include treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD). The decision marks the first authorized medicine in the EU for this rare autoimmune condition. Uplizna is already authorized in the […]
Europe: B-Cell Therapy Moves Into IgG4-Related Disease Read More »
